Back to Directory

Oladapo Alli

Email

oladapo.alli@nih.gov

Phone

(240) 627-3593

Institution

Pharmaceutical Affairs Branch, Division of AIDS

Address

Pharmaceutical Affairs Branch
Division of AIDS/OCSO/NIAID/NIH
5601 Fishers Lane
Room 9E16 MSC #9832
Bethesda, MD 20892-3593
USA

Request an Update

Affiliated Studies

P1112: Monoclonal Antibody PK Study

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

Research Area

Study Status